Dr. Jonas C.T. Wang is a Partner at Sycamore Ventures. He is responsible for life sciences/ biotech ventures.

Dr. Wang has over 30 years experience in Healthcare R&D management and business development. Before becoming a venture capitalist in mid-2001, he was Vice President, Research and Technology of Johnson & Johnson Consumer Products Worldwide RD&E responsible for the development of research strategy, new product technology, patent strategy, competitive intelligence, and new measurement methodology for Skin and Hair Care products. He was also a Corporate Director of Johnson & Johnson Topical Formulations and Drug Delivery Technology Resource Center (TRC), responsible for the applied research of topical formulations and drug delivery systems for all Johnson & Johnson sister companies. Prior to joining J&J, Dr. Wang was Associate Director of Basic Pharmaceutics, the Pharmaceutical Research Institute of Bristol-Myers Squibb Co.

He has been listed in Who's Who in America, and Who's Who in the World, and Strathmore’s Who’s Who in the World. He was a winner of many awards e.g., the Johnson Medal, the highest technical achievement award at Johnson & Johnson Inc., for one of his inventions: anti-wrinkle cream, the Distinguished Alumni award of National Defense Medical Center, the Distinguished Alumni award of University of Iowa, USA. During his employment with J&J, Dr. Wang developed more than 10 core technologies, filed more than 30 business-related patent applications with 15 patents issued worldwide, and presented over 100 presentations to scientific symposiums. Dr. Wang is experienced in managing technological innovations, core competency, business strategies, competitive intelligence and patent strategies. In 2000, Dr. Wang participated at the Congressional Business Summit in Washington, D. C., in leading the group exploring emerging markets in America.

Jonas now is a member of AAPS, CIE, and ACPA, and an associate Director of the biotechnology program of Monte Jade Technological Association – Greater New York Chapter. He also had served as a member of the FDA's Bioavailability & Bioequivalency subcommittees.

Slides: The New Frontier For Venture Capitalists in Biotech